Veradigm (MDRX) Competitors $4.15 +0.05 (+1.22%) As of 04/15/2025 03:51 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsHeadlinesInsider TradesOwnershipSEC FilingsSustainabilityTrendsBuy This Stock MDRX vs. OMCL, HSTM, CRTX, NTCT, VRNT, SLP, RBBN, OSPN, ECX, and UISShould you be buying Veradigm stock or one of its competitors? The main competitors of Veradigm include Omnicell (OMCL), HealthStream (HSTM), Cortexyme (CRTX), NetScout Systems (NTCT), Verint Systems (VRNT), Simulations Plus (SLP), Ribbon Communications (RBBN), OneSpan (OSPN), ECARX (ECX), and Unisys (UIS). Veradigm vs. Omnicell HealthStream Cortexyme NetScout Systems Verint Systems Simulations Plus Ribbon Communications OneSpan ECARX Unisys Veradigm (NASDAQ:MDRX) and Omnicell (NASDAQ:OMCL) are both small-cap business services companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, community ranking, dividends, profitability, earnings, analyst recommendations, risk, institutional ownership and media sentiment. Do insiders & institutionals have more ownership in MDRX or OMCL? 97.7% of Omnicell shares are held by institutional investors. 2.3% of Veradigm shares are held by insiders. Comparatively, 2.6% of Omnicell shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Does the media favor MDRX or OMCL? In the previous week, Omnicell had 9 more articles in the media than Veradigm. MarketBeat recorded 12 mentions for Omnicell and 3 mentions for Veradigm. Omnicell's average media sentiment score of 1.03 beat Veradigm's score of 0.00 indicating that Omnicell is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Veradigm 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Omnicell 7 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more risk and volatility, MDRX or OMCL? Veradigm has a beta of 0.63, indicating that its share price is 37% less volatile than the S&P 500. Comparatively, Omnicell has a beta of 0.78, indicating that its share price is 22% less volatile than the S&P 500. Does the MarketBeat Community favor MDRX or OMCL? Veradigm received 127 more outperform votes than Omnicell when rated by MarketBeat users. However, 66.84% of users gave Omnicell an outperform vote while only 57.87% of users gave Veradigm an outperform vote. CompanyUnderperformOutperformVeradigmOutperform Votes62957.87% Underperform Votes45842.13% OmnicellOutperform Votes50266.84% Underperform Votes24933.16% Is MDRX or OMCL more profitable? Omnicell has a net margin of 1.13% compared to Veradigm's net margin of 0.00%. Omnicell's return on equity of 3.82% beat Veradigm's return on equity.Company Net Margins Return on Equity Return on Assets VeradigmN/A N/A N/A Omnicell 1.13%3.82%2.07% Which has preferable earnings and valuation, MDRX or OMCL? Omnicell has lower revenue, but higher earnings than Veradigm. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVeradigm$1.53B0.29N/AN/AN/AOmnicell$1.11B1.32$12.53M$0.27116.11 Do analysts rate MDRX or OMCL? Veradigm presently has a consensus target price of $14.00, indicating a potential upside of 237.35%. Omnicell has a consensus target price of $51.00, indicating a potential upside of 62.68%. Given Veradigm's stronger consensus rating and higher probable upside, research analysts clearly believe Veradigm is more favorable than Omnicell.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Veradigm 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50Omnicell 0 Sell rating(s) 4 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33 SummaryOmnicell beats Veradigm on 11 of the 15 factors compared between the two stocks. Remove Ads Get Veradigm News Delivered to You Automatically Sign up to receive the latest news and ratings for MDRX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MDRX vs. The Competition Export to ExcelMetricVeradigmComputer integrated systems design IndustryBusiness SectorNASDAQ ExchangeMarket Cap$449.30M$3.38B$7.02B$7.57BDividend YieldN/A2.31%2.70%4.32%P/E RatioN/A58.1929.7317.81Price / Sales0.2916.72154.9594.61Price / CashN/A34.8531.6134.64Price / BookN/A4.664.564.00Net IncomeN/A$38.20M$195.82M$247.23M7 Day PerformanceN/A-0.06%-0.27%1.45%1 Month Performance-24.55%-10.78%-6.20%-6.24%1 Year Performance-44.30%-6.78%4.18%0.60% Veradigm Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MDRXVeradigm2.041 of 5 stars$4.15+1.2%$14.00+237.3%-44.7%$443.89M$1.53B0.008,000Gap UpOMCLOmnicell2.3429 of 5 stars$31.61+1.3%$51.00+61.3%+16.6%$1.48B$1.11B117.083,800Analyst UpgradeShort Interest ↑Positive NewsHSTMHealthStream3.5703 of 5 stars$32.38+0.7%$32.00-1.2%+33.0%$985.45M$291.65M49.821,140Positive NewsCRTXCortexymeN/A$1.00-1.0%N/A+1.5%$30.15MN/A-0.3455Gap UpNTCTNetScout Systems2.8658 of 5 stars$20.10-0.4%$25.00+24.4%+4.6%$1.44B$821.14M-3.432,296Short Interest ↓Positive NewsVRNTVerint Systems4.743 of 5 stars$16.32+2.8%$30.33+85.9%-43.7%$1.01B$909.19M17.364,400Insider TradeShort Interest ↓Positive NewsGap UpSLPSimulations Plus3.5431 of 5 stars$34.16+4.6%$49.40+44.6%-28.2%$686.99M$78.56M85.40160Analyst DowngradeHigh Trading VolumeRBBNRibbon Communications4.5595 of 5 stars$3.51+1.7%$6.00+70.9%+35.6%$617.53M$833.88M-10.973,107Upcoming EarningsOSPNOneSpan4.4897 of 5 stars$14.39+0.2%$17.63+22.5%+45.4%$549.35M$243.18M19.45790Positive NewsECXECARX2.2259 of 5 stars$1.08+13.7%$3.20+196.3%-45.5%$400.39M$5.56B-2.162,000Short Interest ↑High Trading VolumeUISUnisys4.6271 of 5 stars$3.92+2.3%$6.50+65.8%-28.3%$278.59M$2.01B-1.3916,200Short Interest ↓Positive News Remove Ads Related Companies and Tools Related Companies Omnicell Competitors HealthStream Competitors Cortexyme Competitors NetScout Systems Competitors Verint Systems Competitors Simulations Plus Competitors Ribbon Communications Competitors OneSpan Competitors ECARX Competitors Unisys Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MDRX) was last updated on 4/16/2025 by MarketBeat.com Staff From Our PartnersTwo Unmistakable Patterns Return…The signs suggest we're entering one of those rare periods now. That's why Central Banks are buying gold at...Golden Portfolio | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredIs it CRAZY to still want reliable profits, despite this market?Larry Benedict, the acclaimed "Market Wizard," is calling an emergency briefing now... The same Larry who –...Brownstone Research | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredTariffs. Volatility. Fear. Here’s the Plan.Wall Street's panicking over tariffs. Volatility's back with a vengeance. If you've been glued to the he...Investors Alley | SponsoredTrump 2028 could be a “bonanza” for investorsAs you may have heard, Donald Trump is planning to run for a THIRD term in 2028. Recently he told NBC news ...Paradigm Press | SponsoredMusk’s AI Masterplan – Our #1 AI Stock to Buy NowDid Elon Musk just set the stage for the next AI stock explosion? One 30-year Wall Street veteran thinks so...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Veradigm Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Veradigm With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
